Completed PHASE2 INTERVENTIONAL 2-arm NCT03773952

Safety and Efficacy of PBF-677 in Ulcerative Colitis Patients (ADENOIBD)

A Phase IIa (Proof of Concept), Randomized, Double Blind, Placebo Controlled, Multicenter Clinical Trial to Evaluate the Safety and Efficacy of Oral Treatment With PBF-677 in Patients With Mild to Moderate Ulcerative Colitis

Sponsor: Palobiofarma SL

Conditions Ulcerative Colitis

Interventions PBF-677 Placebo oral capsule

Updated 6 times since 2019 Last updated: Jan 12, 2022 Started: Jul 1, 2018 Primary completion: May 27, 2021 Completion: May 27, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Ulcerative Colitis and is currently completed. Palobiofarma SL leads this study, which shows 6 recorded versions since 2018 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Feb 2022 — Jul 2024 [monthly]

Completed PHASE2

Status: Recruiting → Completed
Jan 2021 — Feb 2022 [monthly]

Recruiting PHASE2
Oct 2020 — Jan 2021 [monthly]

Recruiting PHASE2

▶ Show 1 earlier version

Jan 2019 — Oct 2020 [monthly]

Recruiting PHASE2

First recorded

Jul 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Palobiofarma SL
Qualitecfarma

Data source: Palobiofarma SL

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Madrid, Spain